Philp et al. further validated that the leptin receptor antagonist Alloaca inhibited LNCaP xenograft tumor growth, delayed progression to CRPC in mice, and suggested that leptin receptor blockade combined with androgen axis inhibition is a promising new therapeutic strategy for treating advanced PCa 123. Here, LEPR is linked to neoplasm.